- Phys.org reported on research recently published in an article in Nature Chemical Biology on work by a collaborative team of scientists from MSKCC, the Broad Institute, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, that outlines how they built a new cell culture model that mimics AML in its niche in the bone marrow and makes the search for promising new drugs more effective.
- PMLive reported that the non-profit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will bring together scientists from MSKCC, Rockefeller University and Weill Cornell Medical College and will focus on basic research and early-stage drug discovery up to the ‘proof-of-concept’ stage.
- The Wall Street Journal announced that MSKCC has placed Gelclair(R) on its formulary as the exclusive therapeutic to treat oral mucositis (OM).
Author Archives: Mark
MSKCC in the News: October 3 – October 16
- PMLive announced that the non-profit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will bring together scientists from MSKCC, Rockefeller University and Weill Cornell Medical College and will focus on basic research and early-stage drug discovery up to the ‘proof-of-concept’ stage.
- MSKCC’s Dr. Renier J. Brentjens was quoted in a New York Times article that outlined the impact that new immunotherapies have had on treating patients with melanoma, kidney, lung, breast, ovarian cancer and cancers of the colon, stomach, and head and neck.
- Dr. Peter Bach of MSKCC was quoted in a New York Times article about the soaring costs of prescription drugs.
- MSKCC’s vice president and CIO Patricia C. Skarulis and her colleagues commented on MSKCC’s data sources and strategies in Healthcare Informatics.
MSKCC in the News: September 19 – October 2
- The Economist featured a pair of studies published in Nature Genetics that highlights the impact that genomics has had on cancer research. One study, led by MSKCC’s Chris Sander and colleagues, provides a hierarchical classification of 3,299 tumors from 12 cancer types from the Pan-Cancer data set, using a newly developed algorithmic approach.
- MSKCC is leading an innovative initiative to reduce cancer and cardiovascular health disparities in South Asian immigrant communities in the United States.
- The Courant reported that MSKCC has selected Hartford HealthCare, a multi-hospital health care system in Connecticut, as a pioneering member of the newly formed MSK Cancer Alliance.